How to accelerate mouse model generation without reducing quality
The Drug Discovery World Podcast
Release Date: 02/01/2022
A look behind the scenes of the drug discovery industry
The Drug Discovery World Podcast
This is the latest episode of the free DDW narrated podcast, titled “A look behind the scenes of the drug discovery industry” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: , , and . In the first article, Barry Bunin, PhD, CEO of Collaborative Drug Discovery explores the rise of electronic lab notebooks and why researchers should be transitioning to digital methods of recording data. In the second article, Reece Armstrong sits down with Cancer Research Horizons’ Chief Business Officer, Tony Hickson and CEO of its Therapeutics division, Hamish...
info_outline
DDW Highlights: 22 April 2024
The Drug Discovery World Podcast
The latest episode of the is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The headline news this week all concerns clinical trials for new drugs that could have a significant impact on future patient treatment, including trials testing therapeutics for ALS, cystic fibrosis, gonorrhoea, TB and Parkinson’s. You can listen below, or find The Drug Discovery World Podcast on , and
info_outline
DDW Highlights: 15 April 2024
The Drug Discovery World Podcast
The latest episode of the is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The cancer research news has been coming thick and fast from the American Association of Cancer Research (AACR) Annual Meeting in San Diego this week, so this round-up focuses on drug discovery in oncology. You can to The Drug Discovery World Podcast on , and
info_outline
DDW Highlights: 2 April 2024
The Drug Discovery World Podcast
The latest episode of the is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In another busy week for drug discovery and development, we have seen the FDA approval of a monoclonal antibody for emergency use in Covid-19, the launch of trials into innovative new treatments for urea cycle disorders and alcohol use disorder, and a significant acquisition for Novo Nordisk, as well as the discovery of a new way to target dormant cancer cells. You can listen below, or find...
info_outline
Flow cytometry for drug discovery research
The Drug Discovery World Podcast
This is the latest episode of the free DDW narrated podcast, titled “Flow cytometry for drug discovery research” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: and . In the first article, Dr Amber Miller, Flow Cytometry Scientist, Fortis Life Sciences, says flow cytometry techniques can help our understanding of cancer associated fibroblasts but there is still work to be done. In the second article, Dr Miguel A Tam, and Dr Kenta Yamamoto, BioLegend, examine the evolution, trends and best practices for smooth and efficient workflows for flow...
info_outline
DDW Highlights: 18 March 2024
The Drug Discovery World Podcast
The latest episode of the is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Following the recent AD/PD 2024 conference, which took place on 5-9 March in Lisbon, Portugal, there have been a number of key announcements regarding investigational therapies for neurological disorders, particularly Alzheimer’s disease and Parkinson’s disease. You can listen below, or find The Drug Discovery World Podcast on , and
info_outline
Exploring the potential of a new class of drug candidates
The Drug Discovery World Podcast
In theseries, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with Ahmed Mousa, CEO of Vicore Pharma. Vicore Pharma is exploring the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), and here Mousa provides DDW with an overview of the company’s unique approach, its challenges, its opportunities, and its context in the scientific community. You can listen here, or find The Drug...
info_outline
DDW Highlights: 11 March 2024
The Drug Discovery World Podcast
The latest episode of the is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. It was antibodies hitting the headlines this week, with the discovery of antibodies with potential against a new influenza target, the launch of a Phase I trial to investigate a novel type of bispecific antibody, and the announcement that the FDA will delay approval of donanemab to hold a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee. You can listen below, or...
info_outline
What trends will speed up the journey from clinic to bedside?
The Drug Discovery World Podcast
This is the latest episode of the free DDW narrated podcast, titled: What trends will speed up the journey from clinic to bedside? It covers three articles written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: , and . In the first article, Reece Armstrong speaks to Natalia Mateu, Co-Founder, Jelena Aleksic, Co-Founder and Peter Curran, Chemoinformatics Scientist, about utilising 3D chemistry and AI to get small molecule therapies from the clinic to the bedside. In the second article, we hear from Dr Dina Finan, PhD, Product Manager at 10x Genomics and Dr Nick Downey, PhD, NGS...
info_outline
DDW Highlights: 26 February 2024
The Drug Discovery World Podcast
The latest episode of the is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In a breakthrough for advanced therapies, this week saw the FDA approve the first ever cell therapy for solid tumour cancers, but there were other significant developments in the cell and gene therapy space. You can listen below, or find The Drug Discovery World Podcast on , and
info_outlineThe latest DDW Sitting Down With sponsored podcast features Dominque Bröhl and Evert-Jan Uringa, Scientific Program Managers at Taconic Biosciences who discuss how mouse model generation can be accelerated without any loss of quality.
The generation of genetically engineered custom mouse models can be a lengthy process that conflicts with the general time constraints of the drug discovery and development industry. Finding ways to shorten the time to create new mouse models is tempting but carries the risk of trading short timelines for poor quality.
Taconic Biosciences developed the ExpressMODEL® portfolio of products to achieve the industry’s fastest timelines to study cohort without compromising quality, whether embryonic stem cell (ESC), CRISPR, or random integration transgenic (RITg) methodology is used to generate a mouse model.
Listen in to learn how ExpressMODEL® accelerates timelines and which benefits it brings to your drug discovery and development program.